Comorbidities, bone-sparing agent prescription history and their determinants among postmenopausal women in UK primary care settings: a retrospective database study
- 281 Downloads
Distinguishing oral bisphosphonates from other bone-sparing therapies, this retrospective observational study, first, characterized treated osteoporosis patients in the UK, and secondly, explored factors associated with the risk of discontinuation or switching between therapies. The latter should be considered when evaluating real-world data.
This retrospective observational study evaluated the characteristics of women with postmenopausal osteoporosis, including comorbidities and determinants of treatment patterns with bone-sparing agents.
The UK Clinical Practice Research Datalink was used to identify postmenopausal women (aged ≥50 years) treated with a bone-sparing agent or diagnosed with osteoporosis between 1 January 1993 and 31 December 2008. Two non-mutually-exclusive subpopulations were defined: (1) patients active in the database on 31 December 2008; (2) patients treated with a bone-sparing agent since 1 January 1993. Subpopulation 1 was used to describe patient comorbidities and osteoporosis treatment history, and subpopulation 2 was used to explore the characteristics associated with bone-sparing treatment patterns use via multivariable regression for repeated multinomial responses.
A total of 62,657 individuals met the inclusion criteria; subpopulation 1 comprised 38,469 women (61.4 %), of whom 21,687 received a bone-sparing agent in 2008 (99.7 % oral bisphosphonates and the remainder other agents). Those receiving other agents were more likely to have had previous treatment with bone-sparing agents, to have experienced previous fractures, and to have visited their doctor more frequently. Analyses also identified several comorbidities associated with an increased risk of discontinuation of bone-sparing agents, including heart disease, gastrointestinal disease, and renal failure. Anticonvulsant use was associated with a dramatic increase in the risk of switching.
Several patient characteristics were associated with discontinuation of, or switching between, bone-sparing treatments. Patients receiving bone-sparing medication other than oral bisphosphonates were more likely to have comorbid conditions and a history of fracture and to have taken an oral bisphosphonate previously.
KeywordsPostmenopausal osteoporosis Bone-sparing agents Discontinuation Switching Comorbidities Clinical Practice Research Datalink
Writing assistance was provided by Oxford PharmaGenesis Ltd, funded by Amgen.
Conflicts of interest
The study was sponsored by Amgen Ltd and GlaxoSmithKline plc.
M. Feudjo-Tepie, S. Ferguson, A. Taylor, and C. Critchlow are all Amgen employees. A. Roddam is a GlaxoSmithKline plc employee, but was previously an Amgen employee. J. Bayly is an independent consultant, affiliated with the University of Derby. He has received consultation fees from Amgen.
- 2.Scottish Intercollegiate Guidelines Network (2003) National Clinical Guideline 71: Management of osteoporosis. Available at: http://www.sign.ac.uk/pdf/sign71.pdf. Accessed July 2014
- 3.American Association of Clinical Endocrinologists Osteoporosis Task Force (2001) American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 7:293–312Google Scholar
- 4.International Osteoporosis Foundation (2012) Europe guidelines. Available at: http://www.iofbonehealth.org/europe-guidelines. Accessed 30 April 2014
- 5.Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedPubMedCentralCrossRefGoogle Scholar
- 10.Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91PubMedCrossRefGoogle Scholar
- 12.Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata Y, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459–468PubMedCrossRefGoogle Scholar
- 31.National Institute for Health and Care Excellence (2011) TA160 Osteoporosis – primary prevention. Available at: http://guidance.nice.org.uk/TA160. Accessed 30 April 2014
- 32.National Institute for Health and Care Excellence (2011) TA161 Osteoporosis – secondary prevention. Available at: http://www.nice.org.uk/guidance/ta161/resources/ta161-osteoporosis-secondary-prevention-including-strontium-ranelate-understanding-nice-guidance2. Accessed 30 April 2014
- 34.National Institute for Health and Care Excellence (2014) Osteoporosis overview. Available at: http://pathways.nice.org.uk/pathways/osteoporosis#content=view-node%3Anodes-secondary-prevention-of-osteoporotic-fragility-fractures-in-postmenopausal-women. Accessed 20 July 2015.
- 36.Royal College of Physicians (2011) Falling standards, broken promises: report of the national audit of falls and bone health in older people 2010. Available at: https://www.rcplondon.ac.uk/sites/default/files/national_report.pdf. Accessed 20 July 2015
- 38.Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L, Adami S, Treatment of Osteoporosis in clinical Practice (TOP) Study Group (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 914Google Scholar
- 45.Hippisley-Cox J, Bayly J, Potter J, Fenty J, Parker C. Evaluation of standards of care for osteoporosis and falls in primary care. 2007. Available at: http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/general-practice/evaluation-of-standards-of-care-for-osteoporosis-and-falls-in-primary-care. Accessed 30 April 2015